Biocept and Academic Collaborators to Present Posters at AACR on Circulating Tumor Cells (CTCs)
SAN DIEGO, March 31, 2011 /PRNewswire/ -- Biocept, Inc. today reported that its scientists and academic collaborators will present four posters at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) taking place in Orlando, Florida April 2-6, 2011. The poster presentations are based on studies utilizing Biocept's novel technology for the capture, detection, and analysis of circulating tumor cell (CTCs) in human clinical samples. This technology, Biocept's proprietary OncoCEE™ (Oncology Cell Enrichment and Extraction) platform, enables not only CTC enumeration but also biomarker analysis as demonstrated in several of the posters. These data represent a broad scope of findings from studies involving blood and tumor samples from patients with breast, prostate, lung, colorectal, and ovarian cancers.
Farideh Bischoff, PhD, Director of Translational Research at Biocept, said, "In the poster presentations, data will be discussed that addresses our ability to detect CTCs that do not capture or stain with anti-EpCAM or anti-cytokeratin respectively which is the current method in the market. Also, one of the poster presentations will cover the evaluation of HER2 gene amplification status by FISH (fluorescent in situ hybridization) in intact CTCs within a microfluidic channel. Biocept's proprietary OncoCEE™ platform, which provides the ability to perform cytogenetic and molecular characterization of CTCs, may be an important clinically significant tool. We are excited to be developing innovative testing that may enable advances in the treatment of various cancers."
Additional details for the AACR presentations are as follows: